Post-hoc Analyses of Phase-3 Data with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.088)
Olivier Rascol(Inserm), Susan Huyck(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Hewitt(Glasgow Royal Infirmary), Kenneth Wolski(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tony W. Ho(Johns Hopkins University), Rachel Capece(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Hauser(University of South Florida), David Michelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xianwei Ha(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Sklar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Lines(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fabrizio Stocchi(San Raffaele University of Rome)
Cited by 1
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997